recently, salubris received the notice on clinical trial approval issued by the national medical products administration, and the clinical trial was agreed to start.
sal0114 tablet is a compound independently developed bysalubris, potential candidate for the treatment of clinical depression.
clinical depression is a common mental disease. the studies showthat the prevalence of depressive disorder is up to 2.1%① in china; the life-time prevalence of depressive disorder inchinese adults is 6.8%②, and thepatients with depressive disorder have low utilization of hygiene services andrarely obtain sufficient treatment. most of the currently marketedanti-depressants takes severe weeks to take effect, and the clinical demand isunmet. with the improvement of living standards and the public’s enhancedawareness of mental health, the anti-depressant market is expected to becontinuously expanded. successful r&d and approval for marketing of sal0114tablet will further meet the potential clinical demand and provide the patientswith more treatment options.
①data source: news conference of the information office of the state council onthe report on nutrition and chronic diseases of chinese residents (2020)
②data source: academic sharing | study on epidemiology of depressive disordertreatment in china